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Abstract 
Aims: There are limited data regarding the effect of diabetes mellitus (DM) on the risks of both appropriate and 
inappropriate implantable cardioverter defibrillator (ICD) therapy. The present study was designed to compare the 
outcome of appropriate and inappropriate ICD therapy in patients with or without DM.
Methods and results: The risk of a first appropriate ICD therapy for ventricular tachyarrhythmias (including anti tach-
ycardia pacing and shock) was compared between 764 DM and 1346 non-DM patients enrolled in the national Israeli 
ICD registry. We also compared the risks of inappropriate ICD therapy, and death or cardiac hospitalization between 
diabetic and non-diabetic patients. Diabetic patients were older, were more likely to have ischemic cardiomyopathy, 
lower ejection fraction, atrial fibrillation, and other co-morbidities. The 3-year cumulative incidence of appropriate ICD 
therapy was similar in the DM and non-DM groups (12 and 13%, respectively, p = 0.983). Multivariate analysis showed 
that DM did not affect the risk of appropriate ICD therapy (HR = 1.07, 95% CI 0.78–1.47, p = 0.694) or inappropriate 
therapy (HR = 0.72, 95% CI 0.42–1.23, p = 0.232). However, DM was associated with a 31% increased risk for death 
or cardiac hospitalization (p = 0.005). Results were similar in subgroup analyses including ICD and defibrillators with 
cardiac resynchronization therapy function recipients, primary or secondary prevention indication for an ICD.
Conclusions: Despite a significant excess of cardiac hospitalizations and mortality in the diabetic population, there 
was no difference in the rate of ICD treatments, suggesting that the outcome difference is not related to arrhythmias.
Keywords: Implantable cardioverter defibrillator, Diabetes mellitus, Heart failure, Outcomes
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Several randomized trials have shown that an implanta-
ble cardioverter–defibrillator (ICD) can improve survival 
both among patients who have had sustained ventricular 
tachyarrhythmias and among selected patients who have 
systolic heart failure (HF) without ventricular arrhyth-
mia [1–3]. Patients with evidence of systolic HF with 
intraventricular conduction delay may further benefit by 
implantation of a defibrillator with cardiac resynchroni-
zation function (CRTD) which may improve left ventric-
ular function, prevent heart failure events and survival [4, 
5] while obesity in mild heart failure did not diminish the 
clinical benefit of cardiac resynchronization therapy to 
reduce risk for appropriate ICD therapy [6].
Patients with diabetes mellitus (DM) are at increased 
risk for sudden cardiac death and heart failure [7–14]; a 
previous study suggests that diabetes mellitus may affect 
appropriate and inappropriate ICD discharge [14]. In 
addition, patients with obesity and overweight derived 
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more benefit from CRT. Higher BMI was independently 
associated with better clinical outcome in CRT patients 
[15].
Importantly, little is known about the rates of ICD and 
CRTD therapies in DM patients as compared to non DM 
patients in a real life setting. Thus, we aimed to investi-
gate whether DM may affect appropriate ICD therapy, 
inappropriate ICD therapy, HF hospitalization or death 
among patients enrolled in the Israel ICD registry.
Methods
Study population
The Israeli ICD Database is a prospective, national, multi-
center registry of all patients implanted with an ICD or 
CRT-D for primary and secondary prevention in the 21 
implanting centers of Israel [16, 17]. The registry was ini-
tiated in July, 2010, and prospective follow up was started 
in July, 2011. At baseline, clinical and implantation char-
acteristics were entered by the local electrophysiologist 
into a secure, web based electronic case report form. 
Follow up data for clinical and arrhythmic events were 
obtained from consecutively enrolled patients at 6 month 
intervals.
Patients were classified as having DM if they reported 
treatment for DM at the index hospitalization for device 
implantation or replacement or they were diagnosed with 
DM according to their medical chart. Other clinical vari-
ables collected included basic demographics, indication 
for implantation, electrocardiographic QRS morphology, 
left ventricular ejection fraction, New York Heart Associ-
ation (NYHA) functional class, co-morbidities, and med-
ications. The registry was approved by the institutional 
review board of each participating center and patients 
were included after providing written informed consent.
Endpoints
The endpoints evaluated at follow up included all-cause 
mortality and hospitalization for heart failure as well 
as device therapies that were further classified as being 
appropriate or inappropriate therapies including anti-
tachycardia pacing (ATP) and ICD shock. All intra-
cardiac electrograms of therapies were reviewed by the 
attending electrophysiologist who determined if the ther-
apies were appropriate or not.
Statistical methods
Continuous variables were expressed as mean ±  stand-
ard deviation (SD). Categorical data were summarized as 
frequencies and percentages. Characteristics of patients 
categorized by diabetes status were compared by the Wil-
coxon rank-sum test or Chi square test, as appropriate. 
The probabilities of appropriate ICD therapy, inappropri-
ate ICD therapy and cardiac hospitalization or death by 
DM status were graphically displayed according to the 
method of Kaplan and Meier, with comparison of cumu-
lative events by the log-rank test.
The best subsets regression procedure was used to 
identify significant variables to be included in the mul-
tivariate regression models. For a model with the end-
point of death or cardiac hospitalization the variables 
included age, sex, ischemic heart disease, history of atrial 
fibrillation, NYHA functional class III–IV vs. I–II, creati-
nine level, and DM that was forced into the model. For a 
model with appropriate ICD therapy endpoint the varia-
bles included age, primary vs. secondary prevention indi-
cation, history of atrial fibrillation, QRS width, history of 
any ventricular arrhythmias (non-sustained or sustained 
VT), LVEF, device type (CRTD vs. ICD), and DM which 
was forced into the model. Analyses were conducted with 
SAS software (version 9.4, SAS institute, Cary, NC, USA). 
A 2-sided p value <0.05 was used for declaring statistical 
significance.
Results
From July 2010 through December 2014 a total of 
2110 patients underwent ICD or CRTD implantations 
in 21 centers in Israel for whom follow up data was 
available. Patients were followed for a mean  ±  SD of 
21 ± 10.2 months.
We identified 764 (36%) patients with DM and 1346 
(64%) without DM. The DM patients were significantly 
more ill in a wide variety of ways: they tended to be older, 
and had more co-morbid conditions, including atrial 
fibrillation, chronic lung disease, end stage renal failure 
on dialysis, hypertension, cerebrovascular disease, smok-
ing and sleep apnea (Table 1). Diabetics were more likely 
to have more severe congestive HF, a wider QRS, a lower 
ejection fraction, to undergo CRTD implantation and to 
have ischemic cardiomyopathy.
DM patients implanted with a defibrillator (ICD or 
CRTD) had poor prognosis compared with non- diabetic 
patients implanted with a defibrillator.
At 3  years of follow up, the cumulative event rate of 
cardiac hospitalization or death was 38% among DM 
patients and 29% among no-DM patients (p  <  0.001, 
Fig. 1). The cumulative event rate of death was 12 and 6% 
in DM and no-DM patients, respectively (p = 0.021).
By multivariate analysis (Table  2), DM was associated 
with a significant 31% increased risk for death or cardiac 
hospitalization (p = 0.005), and a trend towards 1.5-fold 
increased risk for death (p = 0.104). During study follow 
up 114  patients  (7%) with a primary prevention indica-
tion  and  82 patients  (16%)  with a secondary prevention 
indication received an appropriate ICD therapy. There 
were also 78 patients (4%) who experienced an inappro-
priate ICD therapy during study follow up. However, 
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there was no significant difference in the incidence of 
appropriate ICD therapy between the groups (Fig. 2). At 
3 years of follow up the cumulative event rate of appro-
priate ICD therapy was 12% in the DM patients and 13% 
in the no-DM patients (p =  0.983). Similarly, there was 
no significant difference in the incidence of inappropriate 
ICD therapy between the groups (Fig. 3) with 5% among 
the DM patients and 6% among the non-DM patients 
(p = 0.075, Fig. 2).
Consistent with these findings, multivariate analysis 
(Table 3) showed that DM did not affect the risk of appro-
priate ICD therapy [hazard ratio (HR) = 1.07, p = 0.694], 
including appropriate shock (HR = 1.13, p = 0.519) and 
appropriate ATP (HR = 1.07, p = 0.743). DM also did not 
affect the risk of inappropriate ICD therapy (HR = 0.72, 
p  =  0.232) including inappropriate shock (HR  =  0.67, 
p  =  0.312), and inappropriate ATP (0.82, p  =  0.517, 
Table 3).
Results were similar in subgroup analyses, demon-
strating that DM was not associated with a significant 
Table 1 Patient characteristics
VA ventricular arrhythmia, CVA cerebrovascular accident, AF atrial fibrillation, 
NYHA New York Heart Association, EF ejection fraction, CRTD cardiac 
resynchronization therapy-defibrillator, ACE angiotensin converter enzyme
Non-diabetics (%) Diabetic (%) p value
N 1346 764
Male 1215 (82) 726 (85) 0.033
Age (mean ± SD) 62.2 ± 14 66.3 ± 9.4 <0.001
Age ≥75 256 (19) 163 (21) 0.154
Prior VA 452 (34) 273 (31) 0.252
Primary prevention 901 (66) 589 (76) <0.001
Ischemic heart disease 904 (67) 625 (82) <0.001
History of AF 254 (19) 170 (22) <0.001
Chronic lung disease 85 (6) 118 (16) <0.001
Smoker 379 (29) 272 (36) 0.003
Dialysis 12 (1) 23 (4) <0.001
Sleep apnea 81 (6) 89 (12) <0.001
Prior CVA 98 (7) 67 (9) <0.001
Atrial fibrillation 30 (2) 35 (1) 0.05
NYHA ≥3 377 (28) 326 (43) <0.001
EF 30.5 ± 11.6 28.0 ± 8.3 <0.001
QRS duration 115.8 ± 29.8 124.6 ± 30.9 <0.01
CRTD 412 (31) 332 (43) <0.001
ACE inhibitor 921 (69) 603 (79) <0.001
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Fig. 1 Cumulative probability of cardiac hospitalization or death 
among diabetic and non-diabetic patients
Table 2 Multivariate analysis: diabetes mellitus and  the 
risk of cardiac hospitalization or death
Adjusted for age, sex, ischemic heart disease, history of atrial fibrillation, NYHA 
functional class III–IV vs. I–II, and creatinine level
Hazard ratio 95% CI p value
Cardiac hospitalization or death 1.31 1.08–1.57 0.005
Death 1.49 0.92–2.41 0.104
Cardiac hospitalization 1.23 1.00–1.50 0.047
Fig. 2 Cumulative probability of appropriate ICD therapy among 
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Fig. 3 Cumulative probability of inappropriate ICD therapy among 
diabetic and non-diabetic patients
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increased risk for an appropriate therapy among ICD 
recipients (HR  =  1.04, p  =  0.843) or among CRT-D 
recipients (HR =  1.14, p =  0.636), among patients with 
a primary prevention (HR = 1.00, p = 0.985) or among 
patients with a secondary prevention indication for an 
ICD (HR = 1.15, p = 0.572).
Discussion
The relationship between glucose metabolism abnormali-
ties and atrial fibrillation [18–20] as well as several other 
types of rhythm disturbances is well established in both 
clinical and experimental models [21–24]. In this con-
text, our findings have several important implications 
regarding the risk associated with DM in a “real world” 
setting among patients implanted with a defibrillator 
(ICD or CRTD). We have shown that (1) DM patients 
implanted with a defibrillator have a significantly higher 
risk for cardiovascular hospitalization or death compared 
with no-DM patients. (2) Despite the poorer prognosis 
among DM patients, there was no significant difference 
in the risk for appropriate or inappropriate ICD therapies 
compared with no-DM patients.
Overall, the DM patient group had a higher risk profile 
for poor outcomes, being older, having more comorbidi-
ties specifically pulmonary disease and renal failure, and 
more advanced heart failure. Thus it could be anticipated 
that they would have a worse prognosis. This finding is 
consistent with other studies of ICD patients who have 
found DM to be an independent risk factor for mortality 
[25–27].
In our study, DM was not associated with an increased 
rate of ICD therapies of any type- including appropriate 
or inappropriate shocks or anti tachycardia pacing. This 
is in concordance with the post hoc sub group analyses of 
the comparison of medical therapy, pacing, and defibril-
lation in heart failure (COMPANION) and multicenter 
automatic defibrillator implantation trial (MADIT)II 
trials that did not find an increased rate of appropriate 
therapies in the DM cohort [28, 29]. However, a recent 
sub-study of the multicenter automatic defibrillator 
implantation trial-reduce inappropriate therapy (MADIT 
RIT) did find that DM patients had a 58% increased risk 
of appropriate therapy (p = 0.003), but a 46% decreased 
risk of inappropriate therapy (p = 0.002) compared to no 
DM patients during a mean follow up of 17 months [14]. 
The authors suggested that the increased risk for appro-
priate ICD therapy might be explained by a reduced auto-
nomic function or vulnerable myocardium resulting from 
ischemia and fibrosis in DM patients rendering the myo-
cardium more prone to produce ventricular arrhythmias. 
The authors hypothesized that the lower risk of inappro-
priate therapy in DM patients observed in their study 
might be explained by a lower likelihood of DM patients 
experiencing exercise-induced sinus tachycardia or rapid 
ventricular response due to the fact that patients with 
diabetes mellitus may be more immobile and sedentary, 
and may have autonomic dysfunction or neuropathy.
The discrepancies between our findings and the 
MADIT RIT sub study, a primary prevention trial, may 
result from a different patient mix. Our registry included 
much more ischemic cardiomyopathy patients in both 
the diabetics and non-diabetics subgroups (87/67%) than 
MADIT RIT (64/48%). Our registry did include 30% 
implanted for secondary prevention—with far more non-
diabetics in the high arrhythmia risk secondary preven-
tion group (Table 1). However, we performed a subgroup 
analysis showing that DM was not associated with a 
significant increased risk for an appropriate or inappro-
priate therapy both among patients with a primary pre-
vention or among patients with a secondary prevention 
indication for an ICD.
Our findings indicate that although DM patients do 
have a poor prognosis, the excess in mortality or hospi-
talization for heart failure is not due to ventricular tachy-
arrhythmias. DM causes other forms of heart failure not 
amenable to device therapy such as heart failure with a 
normal ejection fraction, thus the ICD may not prevent 
mortality from this form of heart failure. Some stud-
ies have found DM to be a risk factor for sudden cardiac 
arrest [8–11, 30] which is predominantly due to ventricu-
lar arrhythmias [31]. DM was thought to cause repolari-
zation abnormalities, predisposing to these arrhythmias 
[12]. This assumption needs reconsideration.
Our findings show that attempts to reduce the excess 
cardiac mortality in DM patients should not focus 
on the treatment of arrhythmia, but on other aspects 
of diabetic treatment. Although glycemic control in 
the past did not improve cardiovascular outcomes 
of diabetic patients [32], newer treatment modalities 
have been promising. Recent studies have shown that 
Table 3 Multivariate analysis: diabetes mellitus and  the 
risk of appropriate and inappropriate ICD therapies
* Adjusted for age, primary vs. secondary prevention indication, history of atrial 
fibrillation, QRS width, history of any ventricular arrhythmias (non-sustained or 
sustained VT), LVEF, and CRTD
#  Adjusted for age, sex, primary vs. secondary prevention indication, history of 
atrial fibrillation, LVEF, NYHA functional class III–IV vs. I–II, and CRTD
Hazard ratio 95% CI p value
Appropriate therapies* 1.07 0.78–1.47 0.694
Appropriate ATP 1.13 0.79–1.62 0.519
Appropriate shock 1.07 0.70–1.64 0.743
Inappropriate therapies# 0.72 0.42–1.23 0.232
Inappropriate ATP 0.67 0.31–1.46 0.312
Inappropriate shock 0.82 0.44–1.51 0.517
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standard treatment of heart failure may be augmented 
by inhibitors of sodium-glucose cotransporter 2 and 
glucagon-like peptide 1 analogues, both of whom may 
reduce cardiac mortality of DM patients in randomized, 
controlled trials [33–35].
Our other finding was that there was no difference in 
the rate of inappropriate shocks between the two groups. 
DM is a risk factor for development of atrial fibrilla-
tion [7, 13, 36–38] and indeed, more of our patients had 
atrial fibrillation (Table 1), a major cause of inappropri-
ate shocks, and it would be anticipated that the rate of 
inappropriate shocks would be increased. Evidence based 
programming of these devices has greatly decreased the 
rate of inappropriate therapies especially in diabetics [14] 
and indeed several centers contributing to the registry 
were participants in successful programming trials dur-
ing the course of follow up, which may explain why there 
was no difference in the rate of inappropriate therapies 
[14, 39].
There other possible explanations for our findings. 
Current medical regimens have effectively reduced the 
rate of ICD therapies to the point that ICD implanta-
tion in non-ischemic cardiomyopathy is not beneficial, 
and this may be true in ischemic cardiomyopathy as well. 
However, a significant difference did remain in the other 
cardiovascular outcomes.
A limitation of our study is the designation of patients 
as diabetics based on self-reporting rather than labora-
tory results such as serum glucose or glycosylated hemo-
globin (HbA1c) levels that constitute the criteria for the 
diagnosis of diabetes. Missing also is data regarding the 
length of time since diagnosis and the degree of glyce-
mic control and non-cardiac organ failure. Some patients 
classified as non-diabetics at entry may have developed 
diabetes during the follow up period, however the study 
mean follow up of 22 months would not be expected to 
cause target organ damage.
In summary, based on the data from the Israeli ICD 
registry we conclude that DM patients implanted with 
ICDs have increased mortality and hospitalizations as 
compared to no DM patients, but a similar rate of appro-
priate and inappropriate therapies. Further attempts to 
reduce the excess mortality and morbidity associated 
with DM in heart disease should target other aspects of 
heart failure in this high risk population.
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